CTLA4 and hepatitis A virus infection: Our data from n = 106 stage III/IV melanoma patients who received combinational ICB therapy with anti-PD-1 and anti-CTLA4 identifies age, but not underlying herpes virus immunity or peripheral TEM subsets as the major variable associated with the risk for immune-checkpoint associated hepatitis.